查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806329

自體免疫疾病診斷市場（按產品、檢測、樣本類型、適應症和最終用戶分類）—2025 年至 2030 年全球預測

Autoimmune Disease Diagnostics Market by Product, Test, Sample Type, Indication, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

自體免疫疾病診斷市場預計到 2024 年將達到 58 億美元，到 2025 年將達到 62.2 億美元，到 2030 年將達到 89 億美元，複合年成長率為 7.38%。

主要市場統計數據
基準年2024年 58億美元
預計2025年 62.2億美元
預測年份 2030 89億美元
複合年成長率（%） 7.38%

無與倫比的分析嚴謹性和新技術進步為自體免疫疾病診斷的新時代奠定了基礎

自體免疫疾病的日益流行，推動了對兼具準確性、快速性和可靠性的診斷解決方案的需求。臨床醫生和實驗室專業人員面臨越來越大的鑑別複雜病理的壓力，因此快速識別免疫異常的能力至關重要。在此背景下，創新技術與先進分析技術的融合正在改變自體免疫疾病的識別和監測方式，最終改善患者預後並最佳化護理路徑。

利用最尖端科技和以患者為中心的方法，實現自體免疫疾病診斷的模式轉移

自體免疫診斷領域正在經歷模式轉移，這得益於次世代定序、新型生物標記發現和照護現場技術的整合。單一標記檢測的時代已經一去不復返；如今，多重免疫學檢測組合能夠全面洞察複雜的免疫反應，從而實現精準的疾病分類和個性化的治療策略。這種轉變正在重新定義實驗室科學與臨床決策之間的關係，促進更具協作性、多學科的病患管理方法。

評估2025年美國新關稅政策對自體免疫疾病診斷市場的深遠影響

2025年美國修訂的關稅政策將為自體免疫診斷供應鏈帶來新的複雜性。進口檢測試劑套件和專用設備零件的關稅上調，促使製造商重新評估籌資策略，許多製造商正在探索近岸外包選項以緩解成本壓力。隨著製造成本的上升，企業正在尋求透過流程最佳化和與策略供應商合作來保護淨利率。

解讀影響診斷創新的產品、測試、檢體、適應症和最終用戶類別的關鍵市場區隔動態

了解市場區隔的細微差別，有助於診斷服務提供者客製化產品以滿足客戶需求。將耗材和檢測試劑套件與檢測設備進行比較，可以發現耗材部分通常是經常性收益來源，而檢測設備則是實驗室基礎設施的策略性資本投資。透過客製化產品系列平衡這些依賴關係，公司可以最佳化現金流，同時與診斷實驗室和醫院建立長期合作夥伴關係。

探索美洲、中東和非洲以及亞太地區自體免疫診斷市場的區域差異和市場促進因素

自體免疫診斷的區域動態反映了臨床重點、法規環境和醫療服務模式的多樣性。在美洲，對精準醫療的高度重視推動了多重檢測和次世代定序檢測的快速應用，而完善的報銷框架也促進了公立和私立醫療機構的可及性。同時，供應商正在擴大區域配送中心，以簡化物流並提升服務應對力。

評估推動自體免疫疾病診斷創新的主要企業的競爭策略和策略聯盟

領先的診斷公司正在部署多管齊下的策略，以確保在自體免疫疾病檢測領域中佔據競爭優勢。策略聯盟、合資企業和授權協議正在推動新型檢測化學方法和數位分析能力的快速整合。透過這些夥伴關係關係，各公司可以共用開發風險和資本投入，同時加速突破性診斷產品的上市時間。

制定可行的策略建議，幫助產業領導者應對市場波動並抓住診斷市場機會

產業領導者必須優先將先進的分析平台與現有的實驗室資訊系統整合，以挖掘更深入的診斷見解。建立強大的數據管道，使企業能夠利用真實世界證據，提升檢測性能，識別新的生物標記特徵，並透過令人信服的臨床檢驗支持監管申報。

揭示這項全面的自體免疫疾病診斷市場研究背後嚴謹的調查方法和分析框架

本研究採用多維度的調查方法，旨在提供對自體免疫診斷市場的客觀全面分析。主要研究包括訪談關鍵意見領袖、實驗室主任和採購專家，以收集新興需求、技術偏好和購買行為的定性見解。同時，次要研究則系統性地回顧了科學文獻、監管備案文件和專利資料庫，以追蹤技術創新軌跡和核准時間表。

綜合闡述自體免疫疾病診斷策略重要性的關鍵見解與未來觀點

這些見解的綜合體現出，市場正處於轉型期，其特點是技術融合、監管格局不斷變化以及對個人化診斷的日益重視。隨著多重免疫測量、次世代定序和數位分析成為臨床工作流程的核心，相關人員必須保持敏捷，抓住新機會，並回應不斷變化的臨床需求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 推出遠端醫療、整合智慧型手機連線的家庭自體免疫疾病檢測套組
  • 採用數位健康平台進行遠端訂購和解釋自體免疫診斷測試的人數激增
  • 擴展個人化蛋白質體學和代謝體學學生物標記組用於第 1 型糖尿病的預測診斷
  • 基於液態生物檢體的遊離DNA甲基化檢測在監測多發性硬化症治療效果的應用
  • 開發用於臨床快速自體免疫診斷的照護現場多重生物標記檢測裝置
  • 將人工智慧演算法融入免疫檢測分析以提高診斷準確性
  • 使用次世代定序抗體組合進行類風濕性關節炎和狼瘡的早期檢測

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章自體免疫疾病診斷市場（按產品）

  • 耗材和檢測試劑套件
  • 裝置

第9章自體免疫疾病診斷市場（按測試）

  • 自體抗體和免疫學檢測
  • 發炎標記物
  • 定期進行實驗室檢查

第 10 章自體免疫疾病診斷市場（按樣本類型）

  • 血
  • 唾液
  • 尿

第 11 章自體免疫疾病診斷市場（按適應症）

  • 器官特異性自體免疫疾病診斷
    • 葛瑞夫茲氏病
    • 橋本氏症
    • 多發性硬化症
    • 1型糖尿病
  • 自體免疫疾病的系統性診斷
    • 類風濕性關節炎（RA）
    • 全身性紅斑性狼瘡（SLE）
    • 系統性硬皮症（硬皮症）

第 12 章自體免疫疾病診斷市場（按最終用戶）

  • 門診治療中心
  • 診斷實驗室
  • 醫院和診所
  • 研究機構

13.美國自體免疫免疫疾病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲的自體免疫疾病診斷市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區自體免疫疾病診斷市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AESKU.GROUP GmbH & Co. KG
    • Bio-Rad Laboratories, Inc.
    • BioAgilytix Labs
    • Biogenuix Medsystems Private Limited
    • bioMerieux SA
    • Danaher Corporation
    • DSS Imagetech Pvt. Ltd.
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd.
    • Grifols, SA
    • Hemagen Diagnostics, Inc.
    • Labcorp Holdings Inc.
    • Medical & Biological Laboratories Co. Ltd
    • Menarini Group
    • Merck KGaA
    • Progentec Diagnostics, Inc.
    • Quest Diagnostics
    • Revvity, Inc.
    • RSR Limited
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • Werfen Group

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-436901065F36

The Autoimmune Disease Diagnostics Market was valued at USD 5.80 billion in 2024 and is projected to grow to USD 6.22 billion in 2025, with a CAGR of 7.38%, reaching USD 8.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.80 billion
Estimated Year [2025] USD 6.22 billion
Forecast Year [2030] USD 8.90 billion
CAGR (%) 7.38%

Setting the Stage for a New Era in Autoimmune Disease Diagnostics Through Unparalleled Analytical Rigor and Emerging Technological Advances

The increasing prevalence of autoimmune disorders has amplified the need for diagnostic solutions that combine precision, speed, and reliability. As clinicians and laboratory professionals face growing demands to distinguish among complex disease presentations, the ability to pinpoint immune dysregulation swiftly becomes critical. Amid this backdrop, a convergence of innovative technologies and refined analytical techniques is transforming how autoimmune conditions are identified and monitored, ultimately enhancing patient outcomes and optimizing care pathways.

Advancements in immunodiagnostic platforms are reshaping traditional workflows, enabling multiplex assays and high-throughput screening to deliver comprehensive profiles from minimal sample volumes. Integration of machine learning algorithms into diagnostic algorithms further refines signal detection, resulting in reduced false positives and expedited turnaround times. Consequently, laboratories are becoming more agile and responsive, leveraging these technological breakthroughs to meet evolving clinical requirements.

This executive summary synthesizes the most pertinent developments influencing autoimmune disease diagnostics today. It offers a strategic overview designed to inform decision-makers, guiding them through emerging landscape shifts, regulatory influences, and segmentation nuances. By framing the critical drivers and barriers shaping this domain, the introduction sets the stage for a detailed examination of market transformations and actionable recommendations that follow.

Unveiling the Paradigm Shift in Autoimmune Disease Diagnostics Driven by Cutting-Edge Technologies and Patient-Centric Approaches

The autoimmune diagnostics field is experiencing a paradigm shift, propelled by the integration of next-generation sequencing, novel biomarker discovery, and point-of-care technologies. Gone are the days when single-marker tests dominated; today, multiplex immunologic panels offer holistic insights into complex immune responses, enabling precise disease classification and tailored treatment strategies. This shift is redefining the relationship between laboratory science and clinical decision-making, fostering a more collaborative, multidisciplinary approach to patient management.

Furthermore, the rise of patient-centric models has spurred the development of minimally invasive sampling techniques. Saliva- and urine-based assays are gaining traction alongside conventional blood tests, as they enhance patient compliance and broaden testing access in outpatient and ambulatory care settings. Consequently, diagnostics providers are investing in robust platforms capable of accommodating diverse sample matrices without compromising analytical performance.

In parallel, regulatory agencies are refining guidelines to ensure assay accuracy and reproducibility while expediting approval pathways for breakthrough technologies. These evolving frameworks are encouraging manufacturers to accelerate innovation cycles, driving competitive differentiation through novel assay chemistries and integrated data analytics. As a result, industry stakeholders are engaging in strategic collaborations and technology licensing agreements to harness complementary capabilities, signaling a new era of collective advancement in autoimmune disease diagnostics.

Assessing the Far-Reaching Consequences of New United States Tariff Policies on the Autoimmune Disease Diagnostics Market Through 2025

The introduction of revised United States tariff policies in 2025 has injected new complexities into the supply chain for autoimmune diagnostics. Increased duties on imported assay kits and specialized instrument components have led manufacturers to reevaluate sourcing strategies, with many exploring nearshoring options to mitigate cost pressures. As production costs climb, companies are seeking to preserve margins through process optimization and strategic supplier partnerships.

Moreover, the elevated tariffs have prompted a reassessment of distribution networks. Distributors and laboratory purchasers are negotiating pricing models more aggressively and exploring consolidated procurement agreements to achieve economies of scale. In response, diagnostics companies are offering value-added services-such as instrument maintenance packages and reagent leasing programs-to differentiate their value propositions and maintain customer loyalty amid pricing volatility.

Despite these headwinds, the industry has demonstrated resilience. Manufacturers are leveraging local contract manufacturing and in-market reagent assembly to offset tariff impacts. Additionally, investments in modular instrument design are enabling rapid component interchangeability, which reduces reliance on specific imported parts. Through these adaptive measures, stakeholders are maintaining supply continuity and safeguarding analytical quality, ensuring that patients continue to receive timely and accurate autoimmune disease diagnoses.

Deciphering Critical Market Segmentation Dynamics Across Product, Test, Sample, Indication, and End User Categories Shaping Diagnostic Innovation

A nuanced understanding of market segmentation reveals how diagnostic providers can tailor their offerings to distinct customer needs. When examining consumables and assay kits alongside instruments, it becomes clear that the consumables segment often drives recurring revenue streams, whereas instruments represent strategic capital investments in laboratory infrastructure. By aligning product portfolios to balance these dependencies, companies can optimize cash flow while fostering long-term partner relationships with diagnostic laboratories and hospitals.

Shifting focus to test categories underscores the critical role of autoantibody and immunologic assays in delivering specificity, while inflammatory marker tests support broader disease monitoring applications. Routine laboratory tests continue to form the diagnostic backbone, particularly in primary care settings where screening for autoimmune indicators often precedes specialized analysis. Integrating these test modalities within a cohesive diagnostic ecosystem empowers clinicians to navigate the full spectrum of patient presentations more effectively.

Sample type considerations further refine targeting strategies. Blood remains the gold standard for most applications, yet saliva and urine matrices offer compelling advantages for decentralized testing. By developing platforms that accommodate diverse sample inputs, companies can unlock new end-user segments, from research institutions exploring novel biomarkers to ambulatory centers seeking rapid, noninvasive diagnostics.

Considering disease indication, organ-specific diagnostics for conditions such as Graves' disease, Hashimoto's thyroiditis, multiple sclerosis, and type 1 diabetes continue to expand alongside systemic autoimmune panels for rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. This dual focus underscores the importance of tailored assay development and robust clinical validation protocols. Finally, end-user segmentation-spanning ambulatory care centers, diagnostic laboratories, hospitals and clinics, and research institutions-highlights the importance of customized support services, training programs, and localized marketing initiatives to maximize adoption and utilization.

Exploring Regional Variations and Growth Drivers Across the Americas, Europe Middle East Africa, and Asia-Pacific Autoimmune Diagnostics Markets

Regional dynamics in autoimmune diagnostics reflect a mosaic of clinical priorities, regulatory environments, and healthcare delivery models. In the Americas, the emphasis on precision medicine is driving rapid adoption of multiplex and next-generation sequencing-based assays, with well-established reimbursement frameworks facilitating access in both public and private healthcare settings. Meanwhile, suppliers are expanding regional distribution hubs to streamline logistics and enhance service responsiveness.

Across Europe, the Middle East and Africa, regulatory harmonization efforts are influencing market entry strategies. In Europe, robust centralized approval mechanisms support the integration of innovative diagnostic technologies, while in many Middle Eastern and African markets, capacity-building initiatives are fostering collaborations between local laboratories and global diagnostics providers. These partnerships are critical for addressing infrastructure gaps and training needs, ultimately improving diagnostic reach and reliability in emerging markets.

The Asia-Pacific region presents a tapestry of growth opportunities characterized by diverse regulatory landscapes and burgeoning investment in healthcare infrastructure. Countries with rapidly expanding laboratory networks are prioritizing the implementation of high-sensitivity immunoassays to tackle rising autoimmune disease prevalence. Concurrently, local manufacturers are partnering with multinational firms to localize production, reducing lead times and enhancing affordability for large patient populations. Collectively, these regional strategies underscore the need for flexible market entry models that accommodate varied clinical, regulatory, and economic conditions.

Evaluating Competitive Strategies and Strategic Collaborations Among Leading Companies Fueling Innovation in Autoimmune Disease Diagnostics

Leading diagnostics companies are deploying multifaceted strategies to secure competitive advantage in autoimmune disease testing. Strategic collaborations, joint ventures, and licensing agreements are enabling rapid integration of novel assay chemistries and digital analytics capabilities. Through these partnerships, firms are accelerating time to market for breakthrough diagnostics while sharing development risks and capital investments.

Simultaneously, several companies are investing in modular instrument platforms that support a broad assay menu, thereby enhancing flexibility for end users and creating cross-selling opportunities for consumables and reagents. This integrated approach encourages laboratory consolidation around a single ecosystem, fostering long-term customer loyalty and driving higher lifetime value per account.

Moreover, a growing number of market leaders are enhancing their digital service offerings by embedding cloud-based data management and remote monitoring solutions into instrumentation. These capabilities not only improve operational efficiency and predictive maintenance but also enable real-time data analytics for epidemiological surveillance and cohort studies. By leveraging these digital infrastructures, companies are creating new avenues for value-added services and reinforcing their roles as strategic partners in clinical research and patient care.

Formulating Actionable Strategic Recommendations to Empower Industry Leaders to Navigate Disruption and Capitalize on Diagnostic Market Opportunities

Industry leaders must prioritize the integration of advanced analytics platforms with existing laboratory information systems to unlock deeper diagnostic insights. By establishing robust data pipelines, organizations can harness real-world evidence to refine assay performance, identify emerging biomarker signatures, and support regulatory submissions with compelling clinical validation.

In addition, forging strong alliances with academic research centers and specialized clinical networks will accelerate the co-development of next-generation assays. These collaborative ecosystems foster knowledge exchange and expedite the translation of novel biomarkers into clinically actionable tests. Consequently, companies can create differentiated value propositions and reinforce their reputations as innovation frontrunners.

Executives should also explore localized manufacturing and reagent assembly partnerships to mitigate geopolitical and tariff-related risks. This strategic decentralization ensures supply chain resilience and enhances responsiveness to regional demand fluctuations. Finally, investing in comprehensive training programs for technicians and clinicians will drive assay adoption and optimize diagnostic utility. By coupling product excellence with superior support services, organizations can secure long-term contracts and reinforce their leadership positions in a competitive landscape.

Elucidating the Rigorous Research Methodology and Analytical Framework Underpinning This Comprehensive Autoimmune Diagnostics Market Study

This study employs a multi-faceted research methodology to deliver an unbiased and comprehensive view of the autoimmune diagnostics landscape. Primary research interviews were conducted with key opinion leaders, laboratory directors, and procurement specialists to gather qualitative insights on emerging needs, technology preferences, and purchasing behaviors. In parallel, secondary research encompassed the systematic review of scientific publications, regulatory filings, and patent databases to track innovation trajectories and approval timelines.

Quantitative data was synthesized using a bottom-up analytical framework to ensure consistency across segmentation categories. Cross-validation between primary and secondary sources enhanced data reliability, while triangulation techniques were applied to reconcile discrepancies and verify emerging trends. Competitive benchmarking exercises provided clarity on each leading company's strategic positioning, product portfolios, and partnership networks.

Geographic analysis incorporated regional regulatory nuances, healthcare infrastructure assessments, and distribution channel evaluations. Throughout the study, rigorous quality control protocols-such as data audits and peer reviews-ensured the integrity and accuracy of findings. This robust methodology underpins the strategic recommendations and market insights presented herein, offering stakeholders a credible foundation for informed decision-making.

Synthesis of Core Insights and Forward-Looking Perspectives Cementing the Strategic Importance of Autoimmune Disease Diagnostics

The synthesis of these insights highlights a market in transition, characterized by technological convergence, shifting regulatory landscapes, and heightened emphasis on personalized diagnostics. As multiplex immunoassays, next-generation sequencing, and digital analytics become central to clinical workflows, stakeholders must remain agile to capture emerging opportunities and address evolving clinical demands.

Regional dynamics underscore the importance of tailored market entry strategies that align with local regulatory frameworks and healthcare infrastructure capabilities. Competitive pressures and tariff-related challenges necessitate resilient supply chain models and strategic collaborations to maintain continuity and cost efficiency.

Ultimately, the success of industry players will hinge on their ability to integrate advanced analytics with robust assay development, foster collaborative research ecosystems, and deliver value through comprehensive support services. By embracing these imperatives, organizations can solidify their positions as leaders in the autoimmune diagnostics realm and drive meaningful improvements in patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rise of telemedicine enabled home based autoimmune disease testing kits integrated with smartphone connectivity features
  • 5.2. Surge in adoption of digital health platforms for remote ordering and interpretation of autoimmune diagnostic tests
  • 5.3. Expansion of personalized proteomic and metabolomic biomarker panels for predictive type 1 diabetes diagnostics
  • 5.4. Implementation of liquid biopsy based cell free DNA methylation assays for monitoring multiple sclerosis treatment efficacy
  • 5.5. Development of point of care multiplex biomarker testing devices for rapid autoimmune diagnosis in clinical settings
  • 5.6. Integration of artificial intelligence algorithms in immunoassay analysis for improved diagnostic precision
  • 5.7. Adoption of next generation sequencing autoantibody panels for early rheumatoid and lupus detection

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Autoimmune Disease Diagnostics Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables & Assay Kits
  • 8.3. Instruments

9. Autoimmune Disease Diagnostics Market, by Test

  • 9.1. Introduction
  • 9.2. Autoantibodies & Immunologic Test
  • 9.3. Inflammatory Markers
  • 9.4. Routine Laboratory Tests

10. Autoimmune Disease Diagnostics Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Saliva
  • 10.4. Urine

11. Autoimmune Disease Diagnostics Market, by Indication

  • 11.1. Introduction
  • 11.2. Organ-Specific Autoimmune Disease Diagnostics
    • 11.2.1. Graves' Disease
    • 11.2.2. Hashimoto's Thyroiditis
    • 11.2.3. Multiple Sclerosis
    • 11.2.4. Type 1 Diabetes
  • 11.3. Systemic Autoimmune Disease Diagnostics
    • 11.3.1. Rheumatoid Arthritis (RA)
    • 11.3.2. Systemic Lupus Erythematosus (SLE)
    • 11.3.3. Systemic Sclerosis (Scleroderma)

12. Autoimmune Disease Diagnostics Market, by End Users

  • 12.1. Introduction
  • 12.2. Ambulatory Care Centers
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals & Clinics
  • 12.5. Research Institutions

13. Americas Autoimmune Disease Diagnostics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Autoimmune Disease Diagnostics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Autoimmune Disease Diagnostics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AESKU.GROUP GmbH & Co. KG
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. BioAgilytix Labs
    • 16.3.5. Biogenuix Medsystems Private Limited
    • 16.3.6. bioMerieux SA
    • 16.3.7. Danaher Corporation
    • 16.3.8. DSS Imagetech Pvt. Ltd.
    • 16.3.9. Exagen Inc.
    • 16.3.10. F. Hoffmann-La Roche Ltd.
    • 16.3.11. Grifols, S.A
    • 16.3.12. Hemagen Diagnostics, Inc.
    • 16.3.13. Labcorp Holdings Inc.
    • 16.3.14. Medical & Biological Laboratories Co. Ltd
    • 16.3.15. Menarini Group
    • 16.3.16. Merck KGaA
    • 16.3.17. Progentec Diagnostics, Inc.
    • 16.3.18. Quest Diagnostics
    • 16.3.19. Revvity, Inc.
    • 16.3.20. RSR Limited
    • 16.3.21. Siemens Healthineers AG
    • 16.3.22. Thermo Fisher Scientific Inc.
    • 16.3.23. Trinity Biotech PLC
    • 16.3.24. Werfen Group

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 26. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ROUTINE LABORATORY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ROUTINE LABORATORY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY GRAVES' DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HASHIMOTO'S THYROIDITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS (RA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS (RA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS (SCLERODERMA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC SCLEROSIS (SCLERODERMA), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 113. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 114. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 125. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 126. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 133. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 134. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 141. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 142. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 143. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 147. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 148. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 151. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 152. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 183. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 184. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 185. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 186. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 187. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 191. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 192. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 193. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 195. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 197. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 198. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 199. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 200. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 201. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 204. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 205. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 206. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 207. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 209. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 211. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 212. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 213. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 214. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 215. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 219. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 221. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 223. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 225. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 227. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 228. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 229. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 233. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 234. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 235. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 237. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 239. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 241. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 242. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 243. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 247. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 249. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 251. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 252. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 267. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 270. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 276. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 278. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 280. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2024 (USD MILLION)
  • TABLE 284. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2025-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 290. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ORGAN-SPECIFIC AUTOIMMUNE DISEASE DIAGNO